Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1440311
European Journal of Endocrinology, Vol 144, Issue 4, 311-318
Copyright © 2001 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krassas, G.
Right arrow Articles by Heufelder, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krassas, G.
Right arrow Articles by Heufelder, A.
Articles

Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts

GE Krassas and AE Heufelder

Department of Endocrinology and Metabolism, Panagia Hospital, Thessaloniki, Greece. Krassas@the.forthnet.gr

Thyroid eye disease (TED) is a debilitating disease impairing the quality of life of affected patients. Treatment is often not satisfactory. This review summarizes the existing literature and discusses the most widely used forms of treatment for TED such as glucocorticoids (GCs), and other immunosuppressive agents. GCs are the most commonly used treatment in patients with TED. Other immunosuppressive agents such as cyclosporin A, azathioprin, cyclophosphamide and ciamexone have been used, but the results are modest at best and indicate an unfavorable benefit-risk relationship. Limited experience indicates that methotrexate may be effective even in patients with refractory TED. Somatostatin analogs, octreotide and lanreotide, may provide a valuable, although costly, therapeutic alternative to GCs. Orbital radiotherapy has been used in the management of TED for almost 60 years. However, its beneficial effects have been questioned recently by several studies, the details of which have not yet been published. Other studies have argued in favor of orbital radiotherapy; however, the benefits appear to be limited to improvement of extraocular muscle dysfunction.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
J. L. Wemeau, P. Caron, A. Beckers, V. Rohmer, J. Orgiazzi, F. Borson-Chazot, M. Nocaudie, P. Perimenis, S. Bisot-Locard, I. Bourdeix, et al.
Octreotide (Long-Acting Release Formulation) Treatment in Patients with Graves' Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 841 - 848.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. Ginsberg
Diagnosis and management of Graves' disease
Can. Med. Assoc. J., March 4, 2003; 168(5): 575 - 585.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. E. Krassas, N. Pontikides, T. Kaltsas, A. Dumas, J. Frystyk, J. W. Chen, and A. Flyvbjerg
Free and Total Insulin-Like Growth Factor (IGF)-I, -II, and IGF Binding Protein-1, -2, and -3 Serum Levels in Patients with Active Thyroid Eye Disease
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 132 - 135.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Pasquali, A. Notaro, G. Bonavolonta', P. Vassallo, A. Bellastella, and A. A. Sinisi
Somatostatin Receptor Genes Are Expressed in Lymphocytes from Retroorbital Tissues in Graves' Disease
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5125 - 5129.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 European Society of Endocrinology.